Collegium Pharmaceutical, Inc. COLL Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Pacira BioSciences, Inc.PCRX

——

Other financials

Income statement

See full

Revenue$193.5M+8.9%

Gross profit$117.2M+20.5%

Operating income$30.9M+42.5%

Net income$14.5M+500%

EPS (diluted)$0.40+471%

Balance sheet

See full

Cash & equivalents$289.6M+147%

Total debt$5.2M-19.5%

Total equity$312.4M+33.3%

Total assets$1.7B+1.3%

Cash flow

See full

Operating cash flow$57.1M+3.1%

CapEx$270.0K-66.2%

Free cash flow$56.8M+4.1%

Valuation

See full

Market cap$1.15B+17.9%

Enterprise value$869.67M-0.3%

P/E15.4×-6.9×

P/S1.5×0.0×

Profitability

See full

Gross margin60.7%+3.0pp

Operating margin23.7%+2.3pp

Net margin9.4%+2.8pp

FCF margin41.4%+10.4pp

Returns & leverage

See full

Return on equity27.4%+8.2pp

Debt / equity0×0.0×

Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s contingent consideration fair value adjustments?: Collegium Pharmaceutical, Inc. (COLL) reported contingent consideration fair value adjustments of $0 in Q1 2026.
How has Collegium Pharmaceutical, Inc.'s contingent consideration fair value adjustments changed year-over-year?: Collegium Pharmaceutical, Inc.'s contingent consideration fair value adjustments increased by 100.0% year-over-year, from -$786K to $0.